Medicine
Elzonris 1000 mcg/1 mL injection
Elzonris 1000 mcg/1 mL injection is a prescription medicine containing Tagraxofusp for intravenous use, marketed by Stemline Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in freezer between -25°C and -15°C (-13°F and 5°F). Thaw vials at room…
Key facts
- Active ingredient (INN)
- Tagraxofusp
- Brand
- Elzonris
- Strength
- 1000 mcg/1 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 1 mL
- Marketing authorisation holder
- Stemline Therapeutics
- Manufacturer
- Stemline Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store in freezer between -25°C and -15°C (-13°F and 5°F). Thaw vials at room temperature between 15°C and 25°C (59°F and 77°F) prior to preparation.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX67 Tagraxofusp
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 January 2019
- Identifiers
- RxCUI 2109059, 2109064DailyMed set ID 80eb1080-fe20-4af0-b2a5-a67999923fa8NDC 72187-0401Application BLA761116
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose | 72187-0401-1 | Stemline Therapeutics | 18 January 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Tagraxofusp is a CD123 interaction indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. It is available as injection for intravenous use. MedsAcross supplies Tagraxofusp for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TagraxofuspFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Elzonris prescribing information (Stemline Therapeutics) · U.S. National Library of Medicine, DailyMed
- Elzonris: European public assessment report (EPAR) · European Medicines Agency
Need Elzonris 1000 mcg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.